Cambridge Innovation Capital’s Post

📢Interesting #Review: An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma 🎓 by Dr. Eleni-Myrto Trifylli et al., from National & Kapodistrian University of Athens. 👉Enjoy reading: https://lnkd.in/eXZxA35B #cholangiocarcinoma; #hepatocellularcarcinoma; #immunotherapy; #immune checkpoint inhibitors; #immunoresistance; #tumor microenvironment

Innovation continues to transform modern care for patients with #MultipleMyeloma (MM). New developments with CD38 antibodies and BCMA immunotherapy have clear implications for oncology nurses, who play a pivotal role in the management of MM as caregivers, educators, patient advocates, and conduits for the coordination and delivery of care. In collaboration with the HealthTree Foundation for Multiple Myeloma and #ONS2024, this #PeerView Seminar and Nurse Workshop initiative will feature a panel of expert oncology nurses who will use a series of ten case-based learning sessions to provide guidance on modern patient assessment, therapy selection, dosing, and adverse event management when using CD38 antibody platforms, BCMA immunotherapies, and other innovative therapeutics. Register today and don’t miss this opportunity to join the #oncology #nurse experts Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO, Donna Catamero, ANP-BC, OCN, CCRC, and Charise Gleason NP, MSN, NP-C, AOCN, to take steps to improve patient care! https://bit.ly/MM24L #MedEd #ONS2024 This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi

Got to kind of love the authors for this 'living without stage IV disease is of obvious benefit to the quality of life of patients' - it's obviously not entirely correct- living without stage IV disease isn't only benefiting your QUALITY of life, it means you get QUANTITY of it, too- which is kind of the entire point. It's nice to read a balanced discussion about the risk/ benefit trade-offs, long overdue after those unselected Stage2 trials. Not sure I agree on the solutions -we've been looking for predictive immuno markers for ages now and not very successfully so, we know that micromets are common (the Marsden autopsies?), Melanoma is famous for late recurrences which leaves people with early Melanoma with a Damocles sword hanging over their lives, for some, with considerable psychological impact. So we'd rather have something like a 'surveillance marker'- we've had a planning meeting for #MPNE2024 only last weekend with the MPNEurope community, so it's fresh :)- if we were able to measure whether the immune system was able to control the disease...we'd treat the moment it was failing and otherwise, let everyone in peace...which would actually address both issues: we only expose those in need to the risk of toxicity. And we reassure anyone else.... And 🙏 for the Open Access!

Exposure to UV radiation fuels the malignant melanoma treatment market, with UVA and UVB damaging DNA, leading to mutations. Johnson & Johnson, and Pfizer are key players. Focus on innovative drug development, exemplified by Bristol Myers Squibb's Opdualag, drives market growth. Collaborations like Immatics partnering with Bristol Myers Squibb aim for advanced cancer therapies. Market segments include treatment type, disease, and end-users. North America leads, with Asia-Pacific forecasted for rapid growth. Expected to reach $7.21 billion in 2024, growing at a 12.0% CAGR, and $10.85 billion by 2028. Targeted therapies, patient awareness, and AI integration are key drivers, while early detection tech and precision medicine are emerging trends. Read more https://lnkd.in/gbfqyvf5 #MelanomaTreatment #UVRadiation #Innovation #Collaboration #MarketGrowth #tbrc #thebusinessresearchcompany #marketresearch #marketintelligence

The interesting results of the phase 2b study that evaluated the adjuvant combination of the mRNA-4157 vaccine + pembrolizumab in patients with melanoma were recently published. 🤓 ❗ The Lancet 💉 The risk of recurrence or death was lower in patients treated with combination. 💉 The recurrence-free survival benefit in the combination therapy group was similar in magnitude in both TMB-high and non–TMB-high subgroups. 💉 Most treatment-related adverse events were grade 1–2, including influenza-like symptoms and local injection-site reactions. Phase 3 trial has begun!! https://lnkd.in/ejSU53wD

The Sarcoma Foundation of America is hosting a "Sarcoma Drug Repurposing Webinar" and we would like to invite you to join us. Our colleague, Timothy Stuhlmiller, has been invited as a key speaker at this important event. Jan 18, 2024 1PM - 2:30PM EST This webinar, in collaboration with the CDRC Critical Path Institute (C-Path) Sarcoma Task Force, spotlights an innovative initiative. It delves deep into repurposing existing medications to revolutionize treatment options for sarcoma patients. With a focus on leveraging real-world data, this project underscores the potential of existing drugs in new therapeutic applications. 💡 Why Attend? - Discover cutting-edge approaches in sarcoma research. - Engage with leading experts in the field, including Timothy Stuhlmiller of xCures, Brandi Felser of Sarcoma Foundation of America, William Tap of Memorial Sloan Kettering Cancer Center and Lennie Woods of Clear Cell Sarcoma Foundation - Learn about the integration of real-world data in accelerating cost-effective treatments. - Contribute to a transformative discussion impacting the sarcoma community. Join the conversation and be part of this change. 🔗 Reserve your spot now! https://lnkd.in/gEBVyzdu #SarcomaResearch #DrugRepurposing #PatientEngagement #xCures #Innovation #HealthcareCollaboration

Did you catch some familiar faces on Cincinnati’s Local 12 this past weekend?  CTI’s Medical Director, Richard Curry, MD, and CEO and Chairman, Timothy Schroeder, had the opportunity to sit down with local experts and Medical Reporter, Liz Bonis, to discuss cancer breakthroughs in the healthcare field. Greater Cincinnati has become a prevalent region for clinical research organizations, doctors, and advocates for cancer research, with significant strides made over the past decade. Curry and Schroeder focused on the recent BXQ-350 drug development in clinical trials from Bexion Pharmaceuticals. Aiming to fight cancer and stop neuropathy, a common side effect of chemotherapy. Check out the full report with this link: https://lnkd.in/gnRPwcAt To participate in the ongoing trial at our Clinical Research Center (CRC), visit our website https://lnkd.in/dQ7xux6Y We’re proud to have strong leadership and medical expertise on the CTI team working to #MoveMedicineForwad.  #MovingMedicineForward #AdvancingHealthcareSoltions #CRO #ThinkGlobalActLocal #ClinicalResearch #ClinicalTrials #LeadershipInTheField #BexionPharmaceuticals #BXQ350 #StopNeuropathology #FightCancer #CommonChemoSideEffects #WKRC #Local12 

Our latest research, driven by PandaOmics, identified MYT1 as a promising therapeutic target for breast and gynecological cancers, with our lead compound 21, demonstrating remarkable selectivity and promising in vivo antitumor efficacy. Through structure-based drug design, we optimized potency and physical properties, offering a potential breakthrough in innovative treatment options for these deadly diseases. To read the paper: https://lnkd.in/gb-J463c #CancerResearch #DrugDiscovery #PrecisionMedicine

#DidYouKnow – there are hundreds of clinical trials that melanoma patients can join. You may be able to join a clinical trial before or after you’ve tried other FDA-approved treatments & you will get the standard of care that is the usual FDA-approved treatment for your melanoma subtype. We invite you to review this clinical trial infographic, developed in partnership with Bristol Myers Squibb, to learn more about clinical trials - https://buff.ly/43MfoFT

Capivasertib approved to treat patients with advanced breast cancer The active substance capivasertib is part of a group of medicines called AKT inhibitors. It blocks the effects of proteins called ATK Kinases, which enable cancer cell growth and multiplication. By blocking their action, capivasertib can reduce the growth and spread of the advanced breast cancer and help to destroy cancer cells. https://lnkd.in/dCKtSMWF